Background:
The humoral response against Chlamydia Pneumoniae (CP)-HSP60, an highly immunogenic molecule with high degree of sequence homology with the human HSP60, was found to be highly specific for acute coronary syndromes. Methods: Among 984 patients with unstable angina (UA) included in the SPAI (Stratificazione Prognostica Angina Instabile) Study, we selected 119 subjects with unfavourable and 119 with good outcome (as combined end point: death, myocardial infarction and readmission for UA within 180 days after admission) matched for age, gender, risk factors and clinical presentation. As stable atherosclerotic controls (PVD) we assessed 66 patients scheduled for carotid endarterectomy without evidence of coronary disease (excluded by dobutamine stress echocardiography). In all patients we analized Cp-HSP60 IgG, measured by an in-house ELISA, Cp-IgG and CP-IgA levels, measured by a commercially available microimmunofluorescence assay (Labsystems), with titers > 1:32 regarded as positive. In UA population we also assessed the time course of seropositivity (defined as an ELISA reading of > 0.30) at discharge and at 90 days. Results: In UA, IgG and IgA CP-seropositivity was only found in 58% (vs PVD 80.3% p<0.01) and 21% (vs PVD 30.3%; ns) respectively, but all UA patients on admission were positive (100%) for antibodies against CP-HSP60, conversely only 12% of PVD were positive for antibodies against CP-HSP60. In UA CP-HSP60 antibody titers on admission were not correlated to clinical presentation, outcome, C-reactive protein or Troponin I levels.
In UA, CP-HSP60 antibody titers increased significantly at 90 days [median (range); admission 0.50 (0.3-1.0) vs discharge 0.60 (0.3-1.3) respectively; p < 0.01]. Finally, CP-HSP60 titers in UA were higher in CP-seropositive than seronegative patients, while no difference was observed in PVD. Conclusion: Seropositivity to CP-HSP60 is highly specific for UA and increases significantly up to 90 days, despite stability of IgG and IgA antibody titres against CP, most likely suggesting an antigenic mimicry. Background: At present, the understanding of endogenous expression of factors involved in angiogenesis in the myocardium is incomplete. Therefore, we performed Affymetrix® GeneChip analysis on normal and chronic ischemic myocardium before and during acute ischemia and reperfusion stress in humans. Methods: Myocardial biopsies were sampled at baseline, after 45 min of acute total ischemia, and after 30 min of reperfusion recovery from both normally perfused and chronic reversibly ischemic myocardium in 6 patients undergoing coronary artery by-pass grafting. RNA was isolated, amplified with established techniques, and hybridized to HG_U133A Affymetrix® Genechip arrays. A total of 33 arrays were performed, normalized with the RMA algorithm and analyzed for expression patterns of pro-and anti-angiogenic factors.
Results: Array analysis demonstrated increased baseline expression of VEGF-C and CYR61 angiogenic inducer in chronic ischemic myocardium compared with healthy tissue. VEGF-A expression did not differ between chronic ischemic and normal myocardium, and was induced in response to ischemia in both tissues. Interestingly, expression of several potent anti-angiogenic factors, i.e. thrombospondins and endostatin tended to increase in response to 45 min of acute ischemia in the diseased, ischemic tissue, but not in normally perfused myocardium. Furthermore, chronic ischemic tissue exhibited a fibrotic response to acute ischemia and reperfusion (e.g. increased collagen and fibronectin expression), whereas normal myocardium did not. Conclusion: These findings suggest that, on a transcriptional level, the balance between angiogenesis and fibrosis in the myocardium differs between healthy and chronic ischemic tissue. Although chronic ischemic myocardium expresses pro-angiogenic molecules, this expression seems to be more strongly opposed by expression of anti-angiogenic factors and super-imposed by a fibrotic response. These features should be kept in mind when designing therapeutic angiogenic treatment.
